Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

- Patient Population Type: Advanced Muscle Invasive Bladder Cancer

   - Prior Therapy: One prior therapy for advanced disease

   - Disease: Measurable disease

   - ECOG Performance: 0,1

   - Indication: Histologically Proven Carcinoma of the bladder

   - For female patient of childbearing potential, neither pregnant nor breastfeeding, and
   under active contraception

   - Allergies: No known allergy to one of the study drugs

   - Patient Status:

   - No CNS metastases

   - No peripheral neuropathy > grade1

   - No other serious concomitant illness

   - Fully recovered from any prior therapy

   - Informed Consent: Patient and doctor have signed informed consent

   - Lower Age Limit: Lower age limit >18

   - Upper Age Limit: Upper Age Limit <70

   - ANC: ANC >1500/mm3 or WBC > 3000/mm3

   - Platelets: Platelets >100,000/mm3

   - Creatinine: Creatinine <1.8mg/dL

   - Bilirubin: Bilirubin <=2.0 x ULN

   - SGPT: SGPT (ALT) <=1.5 x ULN (<4xULN if liver metastases present)

   - RBC: Hemoglobin > 9.0g/dL

   - Cardiovascular: No active congestive heart failure, no uncontrolled angina, no
   myocardial infarction within the past 6 months

   - Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma)

   - No prior exposure to Oxaliplatin

   - No cytotoxics or radiation 4 weeks prior to enrolling on protocol

   - PT/PTT normal